Kyverna Therapeutics, Inc. KYTX Income Statement
| FY'25 | FY'24 | ||
|---|---|---|---|
| $133.72M+18.9% | $112.47M+125% | ||
| $36.11M+19.8% | $30.13M+141% | ||
| $169.83M+19.1% | $142.6M+129% | ||
| -$169.83M-19.1% | -$142.6M-129% | ||
| $490K+245% | $142K-24.1% | ||
| $8.52M-43.7% | $15.13M+642% | ||
| -$161.31M-26.5% | -$127.48M-111% | ||
| -$3.64-4.9% | -$3.47+95.8% | ||
| -$168.03M-19.6% | -$140.47M-131% | ||
| -$169.83M-19.1% | -$142.6M-129% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Kyverna Therapeutics, Inc. profitable?
- Kyverna Therapeutics, Inc. is not currently profitable: it reported a net loss of $156.4M over the trailing twelve months.
- What is Kyverna Therapeutics, Inc.'s earnings per share?
- Kyverna Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-3.27.
- Where does Kyverna Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Kyverna Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.